A Versatile Monoclonal Antibody Specific Against Human DAB2IP.

A Versatile Monoclonal Antibody Specific Against Human DAB2IP. Monoclon Antib Immunodiagn Immunother. 2015 Aug;34(4):246-50 Authors: Su Y, Shi F, Zeng Z, Wu X, Zhao Y, Zhang L, Xie Z, Wu Y Abstract Human DAB2 interaction protein (DAB2IP) is a member of Ras-GTPase activating protein family and functions as a tumor suppressor, implying it could serve as a prognostic biomarker in cancers. Here we generated a mouse monoclonal antibody, 2A4, directed against human DAB2IP. This antibody was identified as IgG1 and specifically recognizes DAB2IP in both its native and denatured forms. It will serve as a useful and versatile tool for further mechanistic study and development of the potential prognostic significance of DAB2IP. PMID: 26301927 [PubMed - in process]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

Authors: Huang L, Qiao G, Morse MA, Wang X, Zhou X, Wu J, Hobeika A, Ren J, Lyerly HK Abstract Adoptive T cell immunotherapy with cytokine-induced killer cells (CIKs) has been demonstrated to prolong the survival of patients with advanced non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate whether the expansion of effector T cells and the decrease of regulatory T cells (Tregs) that occurred during the ex vivo generation of DC-CIKs were associated with improved clinical outcome in patients who received treatment. CIKs were generated ex vivo over a 28-day period from the peripheral blood ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Yang L, Wang Y, Wang H Abstract Gastric cancer (GC) is a malignant tumor that negatively impacts human health, which typically presents in the advanced stages of disease in the majority of patients. Despite the development of combination chemotherapy, only a modest survival advantage is gained in patients with GC treated by this method. Recently, cancer immunotherapies have received considerable attention as a viable therapeutic option for GC. Specifically, the immune checkpoint inhibitors, chimeric antigen rector (CAR)-T cells and tumor vaccines, represent immunotherapies that have exhibited promising eff...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, CDK9 may be utilized to evaluate the prognosis and the immune-type of the tumor microenvironment in patients with MSS mCRC. PMID: 31788079 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett. 2019 Dec;18(6):5977-5985 Authors: Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, Saito M, Momma T, Saze Z, Ohki S, Kono K Abstract A small subset of patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS)-colorectal cancer (CRC) benefit from immunotherapy with anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade. Therefore, the aim of the current study was to evaluate t...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Fu C, Zhou N, Zhao Y, Duan J, Xu H, Wang Y Abstract Increasing evidence supports the concept that cancer stem cells (CSCs) are responsible for cancer progression and metastasis, therapy resistance and relapse. In addition to conventional therapies for colon cancer, the development of immunotherapies targeting cancer stem cells appears to be a promising strategy to suppress tumor recurrence and metastasis. In the present study, dendritic cells (DCs) were pulsed with whole-tumor cell lysates or total RNA of CD44+ colon cancer stem cells (CCSCs) isolated from mouse colon adenocarcinoma CT-26 cell cultures and...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
The US Food and Drug Administration approved the immunotherapy as initial treatment of metastatic nonsquamous non-small cell lung cancer (mNSCLC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Brett S. Marro, Jaroslav Zak, Reza Beheshti Zavareh, John R. Teijaro, Luke L. Lairson, Michael B.A. OldstoneSummaryInhibitory receptors (IRs) function as critical regulators of immune responses by tempering T cell activity. In humans, several persisting viruses as well as cancers exploit IR signaling by upregulating IR ligands, resulting in suppression of T cell function (i.e., exhaustion). This allows escape from immune surveillance and continuation of disease. Here, we report the design, implementation, and results of a phenoty...
Source: Cell Reports - Category: Cytology Source Type: research
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Assaf Magen, Jia Nie, Thomas Ciucci, Samira Tamoutounour, Yongmei Zhao, Monika Mehta, Bao Tran, Dorian B. McGavern, Sridhar Hannenhalli, Rémy BosselutSummaryMost current tumor immunotherapy strategies leverage cytotoxic CD8+ T cells. Despite evidence for clinical potential of CD4+ tumor-infiltrating lymphocytes (TILs), their functional diversity limits our ability to harness their activity. Here, we use single-cell mRNA sequencing to analyze the response of tumor-specific CD4+ TILs and draining lymph node (dLN) T cells. Co...
Source: Cell Reports - Category: Cytology Source Type: research
Authors: Magrone T, Magrone M, Jirillo E Abstract BACKGROUNDS: Mast cells (MCs) bear many receptors which allow them to respond to a variety of exogenous and endogenous stimuli. However, MC function is dual since they can initiate pathological events or protect the host against infectious challenges. Involvement of mast cells in various disease: The role of MCs in disease will be analyzed in a broad sense, describing cellular and molecular mechanisms related to their involvement in auto-inflammatory diseases, asthma, autoimmune diseases and cancer. On the other hand, their protective role in the course of bacterial...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Microbiology | Study